CSIMarket
 


Pmv Pharmaceuticals Inc   (PMVP)
Other Ticker:  
 

Pmv Pharmaceuticals Inc 's Working Capital Ratio

PMVP's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




PMVP Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 36.12 % 51.69 % 101.6 % 90.62 % 56.37 %
Y / Y Current Assets Change -15.43 % -12.76 % -14.01 % -17.4 % -16.09 %
Working Capital Ratio MRQ 22.75 24.76 24.65 24.66 36.62
Overall Ranking # # # # #
Seq. Current Liabilities Change 2.4 % -2.58 % -4.37 % 42.7 % 14.11 %
Seq. Current Assets Change -5.92 % -2.14 % -4.4 % -3.91 % -2.95 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 22.75 above Pmv Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry Pmv Pharmaceuticals Inc booked the highest Working Capital Ratio than Pmv Pharmaceuticals Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is PMVP most successful ?
Working Capital Ratio PMVP on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Pmv Pharmaceuticals Inc 's Current Liabilities $ 12 Millions Visit PMVP's Balance sheet
Pmv Pharmaceuticals Inc 's Current Assets $ 265 Millions Visit PMVP's Balance sheet
Source of PMVP's Sales Visit PMVP's Sales by Geography


Cumulative Pmv Pharmaceuticals Inc 's Working Capital Ratio

PMVP's Working Capital Ratio for the trailling 12 Months

PMVP Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 36.12 % 51.69 % 101.6 % 90.62 % 56.37 %
Y / Y Current Assets TTM Growth -15.43 % -12.76 % -14.01 % -17.4 % -16.09 %
Working Capital Ratio TTM 24.21 27.02 30.67 37.35 47.27
Total Ranking TTM # 86 # 136 # 114 # 94 # 61
Seq. Current Liabilities TTM Growth 2.4 % -2.58 % -4.37 % 42.7 % 14.11 %
Seq. Current Assets TTM Growth -5.92 % -2.14 % -4.4 % -3.91 % -2.95 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $11.66 millions, average cumulative Working Capital Ratio decreased to 24.21 below the Pmv Pharmaceuticals Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Working Capital Ratio than Pmv Pharmaceuticals Inc . While Working Capital Ratio overall ranking has improved so far to 86, from total ranking in previous quarter at 126.

Explain Working Capital Ratio
Where is PMVP most successful ?
Working Capital Ratio PMVP on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 30
Healthcare Sector # 43
Within the Market # 86


TTM Working Capital Ratio Statistics
High Average Low
59.69 40.24 24.21
(Mar 31 2021)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Xbiotech Inc   62.44 $ 223.427  Millions$ 3.578  Millions
Cohbar Inc   54.38 $ 19.023  Millions$ 0.350  Millions
Tyra Biosciences Inc   48.73 $ 267.471  Millions$ 5.489  Millions
Nuvation Bio Inc   48.63 $ 681.389  Millions$ 14.011  Millions
Lexaria Bioscience Corp   46.07 $ 6.978  Millions$ 0.151  Millions
Atea Pharmaceuticals Inc   43.62 $ 681.935  Millions$ 15.634  Millions
Atossa Therapeutics Inc   43.02 $ 123.395  Millions$ 2.868  Millions
Artelo Biosciences Inc   42.30 $ 20.303  Millions$ 0.480  Millions
Xenon Pharmaceuticals Inc   41.78 $ 649.176  Millions$ 15.537  Millions
Synaptogenix Inc   39.98 $ 27.329  Millions$ 0.684  Millions
Design Therapeutics Inc   33.47 $ 348.488  Millions$ 10.412  Millions
Kezar Life Sciences Inc   31.15 $ 298.927  Millions$ 9.595  Millions
Merrimack Pharmaceuticals Inc  30.42 $ 13.628  Millions$ 0.448  Millions
Karuna Therapeutics Inc   29.93 $ 1,219.678  Millions$ 40.745  Millions
Nextcure Inc   29.76 $ 175.315  Millions$ 5.891  Millions
Anebulo Pharmaceuticals Inc  28.38 $ 19.815  Millions$ 0.698  Millions
Theseus Pharmaceuticals inc   27.54 $ 214.997  Millions$ 7.806  Millions
Spruce Biosciences Inc   27.43 $ 93.186  Millions$ 3.397  Millions
Cyteir Therapeutics Inc   27.05 $ 157.348  Millions$ 5.816  Millions
Immix Biopharma Inc   26.90 $ 17.391  Millions$ 0.647  Millions
Savara Inc   26.55 $ 137.069  Millions$ 5.163  Millions
Imago Biosciences Inc   25.95 $ 182.040  Millions$ 7.015  Millions
Ironwood Pharmaceuticals inc   25.78 $ 698.994  Millions$ 27.117  Millions
Terns Pharmaceuticals Inc   25.47 $ 190.537  Millions$ 7.481  Millions
Oramed Pharmaceuticals Inc   25.44 $ 160.172  Millions$ 6.297  Millions
Nanoviricides inc   25.37 $ 13.153  Millions$ 0.518  Millions
Eqrx Inc   25.33 $ 1,523.990  Millions$ 60.163  Millions
Infinity Pharmaceuticals Inc   25.28 $ 49.350  Millions$ 1.952  Millions
Morphic Holding inc   25.09 $ 382.410  Millions$ 15.241  Millions
Io Biotech Inc   24.96 $ 157.751  Millions$ 6.321  Millions

Date modified: 2022-11-10T15:51:36+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

BXRO's Profile

Stock Price

BXRO's Financials

Business Description

Fundamentals

Charts & Quotes

BXRO's News

Suppliers

BXRO's Competitors

Customers & Markets

Economic Indicators

BXRO's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071